If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Eiichi Ogawa is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles
Chronic Hepatitis C Medicine & Life Sciences
Ribavirin Medicine & Life Sciences
Hepacivirus Medicine & Life Sciences
Genotype Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Virus Diseases Medicine & Life Sciences
Antiviral Agents Medicine & Life Sciences
Interferons Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2003 2020

Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients

Mitsumoto-Kaseida, F., Murata, M., Takayama, K., Toyoda, K., Ogawa, E., Furusyo, N. & Hayashi, J., Jan 2020, In : Journal of Infection and Chemotherapy. 26, 1, p. 28-32 5 p.

Research output: Contribution to journalArticle

Virus Diseases
Hepatitis B virus
HIV
Hepatitis B Surface Antigens
DNA

Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: An analysis with real world outcomes from a multicentre cohort in Japan

Igarashi, A., Furusyo, N., Ogawa, E., Nomura, H., Dohmen, K., Higashi, N., Takahashi, K., Kawano, A., Azuma, K., Satoh, T., Nakamuta, M., Koyanagi, T., Kato, M., Shimoda, S., Kajiwara, E. & Hayashi, J., Jun 1 2019, In : BMJ open. 9, 6, e023405.

Research output: Contribution to journalArticle

Open Access
Ribavirin
Chronic Hepatitis C
Cost-Benefit Analysis
Japan
Genotype

Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

For the REAL-C Investigators, Sep 1 2019, In : Hepatology International. 13, 5, p. 587-598 12 p.

Research output: Contribution to journalArticle

Hepatitis C
Antiviral Agents
Hepacivirus
Chronic Hepatitis C
Japan
7 Citations (Scopus)

Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study

The Kyushu University Liver Disease Study (KULDS) Group, Jun 2019, In : Hepatology Research. 49, 6, p. 617-626 10 p.

Research output: Contribution to journalArticle

Chronic Hepatitis C
Cohort Studies
Genotype
Infection
Antiviral Agents

Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis

The Kyushu University Liver Disease Study (KULDS) Group, Jan 1 2019, (Accepted/In press) In : Hepatology Research.

Research output: Contribution to journalArticle

Propensity Score
Virus Diseases
Population
Viruses
Therapeutics